An update on tardive dyskinesia: From phenomenology to treatment

Tremor and Other Hyperkinetic Movements

Volumn 3, Issue , 2013, Pages

  Waln, Olga ^a   Jankovic, Joseph ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Akathisia; Dopamine receptor blocking agents; Dystonia; Neuroleptics; Tardive dyskinesia; Tardive syndrome

Indexed keywords

EID: 85114484996     PISSN: None     EISSN: 21608288     Source Type: Journal    
DOI: 10.5334/TOHM.165     Document Type: Review

References (87)

1. Schonecker M. Paroxysmal dyskinesia as the effect of megaphen. Nervenarzt 1957;28:550–553.
2. Faurbye A, Rasch PJ, Petersen PB, Brandborg G, Pakkenberg H. Neurological symptoms in pharmacotherapy of psychosis. Acta Psychiatr Scand 1964;40:10–27, doi: http://dx.doi.org/10.1111/j.1600-0447.1964.tb05731.x.
3. Fahn S, Jankovic J, Hallett M. The tardive syndromes: Phenomenology, concepts on pathophysiology and treatment, and other neuroleptic-induced syndromes. In: Fahn S, Jankovic J, Hallett M, editors. Principles and practice of movement disorders, 2nd ed. Philadelphia, PA: Elsevier Sanders; 2011. p 415– 446.
4. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed., Text Revision (DSM-IV-TR). Washington, DC: American Psychiatric Association; 2000. p 803–805.
5. Polizos P, Engelhardt DM, Hoffman SP, Waizer J. Neurological consequences of psychotropic drug withdrawal in schizophrenic children. J Autism Child Schizophr 1973;3:247–253, doi: http://dx.doi.org/10.1007/BF01538282.
6. Peña MS, Yaltho TC, Jankovic J. Tardive dyskinesia and other movement disorders secondary to aripiprazole. Mov Disord 2011;26:147–152, doi: http://dx.doi.org/10.1002/mds.23402.
7. Albayrak Y, Ekinci O. Duloxetine-associated tardive dyskinesia resolved with fluvoxamine: a case report. J Clin Psychopharmacol 2012;32:723–724, doi: http://dx.doi.org/10.1097/JCP.0b013e3182686619.
8. Birthi P, Walters C, Karandikar N. A rare case of tardive dyskinesia and akathisia induced by citalopram. PM R 2010;2:973–975.
9. Chakrabarti S, Chand PK. Lithium-induced tardive dystonia. Neurol India 2002;50:473–475.
10. Fabiani G, Pastro PC, Froehner C. Parkinsonism and other movement disorders in outpatients in chronic use of cinnarizine and flunarizine. Arq Neuropsiquiatr 2004; 62: 784–788, doi: http://dx.doi.org/10.1590/S0004-282X2004000500008.
11. Seeman P. Dopamine D2 receptors as treatment targets in schizo-phrenia. Clin Schizophr Relat Psychoses 2010;4:56–73, doi: http://dx.doi.org/10. 3371/CSRP.4.1.5.
12. Segman RH, Heresco-Levy U, Finkel B, et al. Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia. Mol Psychiatry 2001;6:225–229, doi: http://dx.doi.org/10.1038/sj.mp.4000842.
13. Glazer WM. Expected incidence of tardive dyskinesia associated with atypical antipsychotics. J Clin Psychiatry 2000;61:21–26.
14. Teo JT, Edwards MJ, Bhatia K. Tardive dyskinesia is caused by maladaptive synaptic plasticity: a hypothesis. Mov Disord 2012;27:1205–1215, doi: http://dx.doi.org/10.1002/mds.25107.
15. Gittis AH, Leventhal DK, Fensterheim BA, Pettibone JR, Berke JD, Kreitzer AC. Selective inhibition of striatal fast-spiking interneurons causes dyskinesia. J Neurosci 2011;31:15727–15731, doi: http://dx.doi.org/10.1523/JNEUROSCI.3875-11.2011.
16. Margolese HC, Chouinard G, Kolivakis TT, Beauclair L, Miller R, Annable L. Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 1: pathophysiology and mechanisms of induction. Can J Psychiatry 2005;50: 541–547.
17. Gunne L, Häggström J, Sjöquist B. Association with persistent neuroleptic-induced dyskinesia of regional changes in brain GABA synthesis. Nature 1984;309:347–349, doi: http://dx.doi.org/10.1038/309347a0.
18. Elkashef AM, Wyatt RJ. Tardive dyskinesia: possible involvement of free radicals and treatment with vitamin E. Schizophr Bull 1999;25:731–740, doi: http://dx.doi.org/10.1093/oxfordjournals.schbul.a033414.
19. Kiriakakis V, Bhatia KP, Guinn NP, Marsden CD. The natural history of tardive dystonia. A long-term follow-up study of 107 cases. Brain 1998;121: 2053–2066, doi: http://dx.doi.org/10.1093/brain/121.11.2053.
20. Cho CH, Lee HJ. Oxidative stress and tardive dyskinesia: Pharmacogenetic evidence. Prog Neuropsychopharmacol Biol Psychiatry 2012;pii: S0278–5846(12)00274-6. doi:10.1016/j.pnpbp.2012.10.018.
21. Cadet JL, Perumal AS. Chronic treatment with prolixin causes oxidative stress in rat brain. Biol Psychiatry 1990;28:738–740, doi: http://dx.doi.org/10. 1016/0006-3223(90)90461-A.
22. Lohr JB, Kuczenski R, Niculescu AB. Oxidative mechanisms and tardive dyskinesia. CNS Drugs 2003;17:47–62, doi: http://dx.doi.org/10.2165/00023210-200317010-00004.
23. Zhang ZJ, Zhang XB, Hou G, Yao H, Reynolds GP. Interaction between polymorphisms of the dopamine D3 receptor and manganese superoxide dismutase genes in susceptibility to tardive dyskinesia. Psychiatr Genet 2003;13:187–192, doi: http://dx.doi.org/10.1097/00041444-200309000-00010.
24. Kulkarni SK, Naidu PS. Pathophysiology and drug therapy of tardive dyskinesia: current concepts and future perspectives. Drugs Today 2003;39:19– 49, doi: http://dx.doi.org/10.1358/dot.2003.39.1.799430.
25. Lerer B, Segman RH, Fangerau H, et al. Pharmacogenetics of tardive dyskinesia: combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism. Neuropsychopharmacology 2002;27:105–119, doi: http://dx.doi.org/10.1016/S0893-133X(02)00293-2.
26. Chen CH, Wei FC, Koong FJ, Hsiao KJ. Association of TaqI A polymorphism of dopamine D2 receptor gene and tardive dyskinesia in schizophrenia. Biol Psychiatry 1997;41:827–829, doi: http://dx.doi.org/10. 1016/S0006-3223(96)00543-4.
27. Tan EC, Chong SA, Mahendran R, Dong F, Tan CH. Susceptibility to neuroleptic-induced tardive dyskinesia and the T102C polymorphism in the serotonin type 2A receptor. Biol Psychiatry 2001;50:144–147, doi: http://dx.doi. org/10.1016/S0006-3223(01)01076-9.
28. Bakker PR, van Harten PN, van Os J. Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions. Mol Psychiatry 2008;13:544–556, doi: http://dx.doi.org/10.1038/sj.mp.4002142.
29. Andreassen OA, MacEwan T, Gulbrandsen AK, McCreadie RG, Steen VM. Non-functional CYP2D6 alleles and risk for neuroleptic-induced movement disorders in schizophrenic patients. Psychopharmacology (Berl) 1997;131: 174–179, doi: http://dx.doi.org/10.1007/s002130050281.
30. Kane JM, Smith JM. Tardive dyskinesia: prevalence and risk factors, 1959 to 1979. Arch Gen Psychiatry 1982;39:473–481, doi: http://dx.doi.org/10. 1001/archpsyc.1982.04290040069010.
31. Rao AS, Camilleri M. Review article: metoclopramide and tardive dyskinesia. Aliment Pharmacol Ther 2010;31:11–19, doi: http://dx.doi.org/10. 1111/j.1365-2036.2009.04189.x.
32. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: systematic review of one-year studies. Am J Psychiatry 2004;161:414–425.
33. Turrone P, Seeman MV, Silvestri S. Estrogen receptor activation and tardive dyskinesia. Can J Psychiatry 2000;45:288–290.
34. Wonodi I, Adami HM, Cassady SL, Sherr JD, Avila MT, Thaker GK. Ethnicity and the course of tardive dyskinesia in outpatients presenting to the motor disorders clinic at the Maryland psychiatric research center. J Clin Psychopharmacol 2004;24:592–598, doi: http://dx.doi.org/10.1097/01.jcp. 0000144888.43449.54.
35. Tarsy D, Baldessarini RJ. Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics? Mov Disord 2006;21:589–598, doi: http://dx.doi.org/10.1002/mds.20823
36. Bhidayasiri R, Boonyawairoj S. Spectrum of tardive syndromes: clinical recognition and management. Postgrad Med J 2011;87:132–141, doi: http://dx. doi.org/10.1136/pgmj.2010.103234.
37. Orti-Pareja M, Jimenez-Jimenez FJ, Vasquez A, et al. Drug-induced tardive syndromes. Parkinsonism Relat Disord 1999;5:59–65, doi: http://dx.doi. org/10.1016/S1353-8020(99)00015-2.
38. Kane JM, Woerner M, Borenstein M, Wegner J, Lieberman J. Integrating incidence and prevalence of tardive dyskinesia. Psychopharmacol Bull 1986;22:254–258.
39. Kang UJ, Burke RE, Fahn S. Natural history and treatment of tardive dystonia. Mov Disord 1986;1:193–208, doi: http://dx.doi.org/10.1002/mds. 870010305.
40. Morgenstern H, Glazer WM. Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications: results of the Yale tardive dyskinesia study. Arch Gen Psychiatry 1993;50: 723–733, doi: http://dx.doi.org/10.1001/archpsyc.1993.01820210057007.
41. Mejia NI, Jankovic J. Tardive dyskinesia and withdrawal emergent syndrome in children. Expert Rev Neurother 2010;10:893–901, doi: http://dx.doi. org/10.1586/ern.10.58.
42. Lim TT, Ahmed A, Itin I, Gostkowski M, Rudolph J, Cooper S, Fernandez HH. Is 6 months of neuroleptic withdrawal sufficient to distinguish drug-induced parkinsonism from Parkinson’s disease? Int J Neurosci 2013;123: 170-174.
43. Trollor JN, Chen X, Chitty K, Sachdev PS. Comparison of neuroleptic malignant syndrome induced by first-and second-generation antipsychotics. Br J Psychiatry 2012;201:52–56.
44. Jankovic J. Tardive syndromes and other drug-induced movement disorders. Clin Neuropharmacol 1995;18:197–214, doi: http://dx.doi.org/10. 1097/00002826-199506000-00001.
45. Stacy M, Cardoso F, Jankovic J. Tardive stereotypy and other movement disorders in tardive dyskinesias. Neurology 1993;43:937–941, doi: http://dx.doi. org/10.1212/WNL.43.5.937.
46. Mehanna R, Jankovic J. Respiratory disorders associated with dystonia. Mov Disord 2012; 27: 1816–1819, doi: http://dx.doi.org/10.1002/mds. 25269.
47. Yassa R, Lal S. Respiratory irregularity and tardive dyskinesia. A prevalence study. Acta Psychiatr Scand 1986;73:506–510, doi: http://dx.doi.org/10.1111/j.1600-0447.1986.tb02717.x.
48. Burke RE, Kang UJ, Jankovic J, Miller LG, Fahn S. Tardive akathisia: an analysis of clinical features and response to open therapeutic trials. Mov Disord 1989;4:157–175, doi: http://dx.doi.org/10.1002/mds.870040208.
49. Fountoulakis KN, Samara M, Siapera M, Iacovides A. Tardive Tourette-like syndrome: a systematic review. Int Clin Psychopharmacol 2011;26: 237–242, doi: http://dx.doi.org/10.1097/YIC.0b013e32834aa924.
50. Stacy M, Jankovic J. Tardive tremor. Mov Disord 1992;7:53–57, doi: http://dx.doi.org/10.1002/mds.870070110.
51. Tominaga H, Fukuzako H, Izumi K, et al. Tardive myoclonus. Lancet 1987;1:322, doi: http://dx.doi.org/10.1016/S0140-6736(87)92042-3.
52. Lorberboym M, Treves TA, Melamed E, Lampl Y, Hellmann M, Djaldetti R. [123I]-FP/CIT SPECT imaging for distinguishing drug-induced parkinsonism from Parkinson’s disease. Mov Disord 2006;21:510–514, doi: http://dx.doi.org/10.1002/mds.20748.
53. Bower JH, Dickson DW, Taylor L, Maraganore DM, Rocca WA. Clinical correlates of the pathology underlying parkinsonism: a population perspective. Mov Disord 2002;17:910–916, doi: http://dx.doi.org/10.1002/mds. 10202.
54. Foubert-Samier A, Helmer C, Perez F, et al. Past exposure to neuroleptic drugs and risk of Parkinson disease in an elderly cohort. Neurology 2012;79:1615– 1621, doi: http://dx.doi.org/10.1212/WNL.0b013e31826e25ce.
55. Kuo SH, Jankovic J. Tardive Gait. Clin Neurol Neurosurg 2008;110:198– 201, doi: http://dx.doi.org/10.1016/j.clineuro.2007.09.013.
56. Langan J, Martin D, Shajahan P, Smith DJ. Antipsychotic dose escalation as a trigger for Neuroleptic Malignant Syndrome (NMS): literature review and case series report. BMC Psychiatry 2012;12:214, doi: http://dx.doi. org/10.1186/1471-244X-12-214.
57. Ford B, Greene P, Fahn S. Oral and genital tardive pain syndromes. Neurology 1994;44:2115–2119, doi: http://dx.doi.org/10.1212/WNL.44.11. 2115.
58. Schneider SA, Dusek P, Hardy J, Westenberger A, Jankovic J, Bhatia KP. Genetics and pathophysiology of neurodegeneration with brain iron accumulation (NBIA). Current Neuropharmacol 2013;11:59–79.
59. Baizabal-Carvallo JF, Bonnet C, Jankovic J. Movement disorders in systemic lupus erythematosus and the antiphospholipid syndrome. J Neurol Transm 2013 (in press). [Epub ahead of print.]
60. Baizabal-Carvallo JF, Stocco A, Muscal E, Jankovic J. The spectrum of movement disorders in children with anti-NMDA receptor encephalitis. Mov Disord 2013;28:543–547, doi: http://dx.doi.org/10.1002/mds.25354.
61. Baizabal-Carvallo JF, Jankovic J. Movement disorders in autoimmune diseases. Mov Disord 2012;27:935–946, doi: http://dx.doi.org/10.1002/mds. 25011.
62. Blanchet PJ, Popovici R, Guitard F, Rompré PH, Lamarche C, Lavigne GJ. Pain and denture condition in edentulous orodyskinesia: comparisons with tardive dyskinesia and control subjects. Mov Disord 2008;23:1837–1842, doi: http://dx.doi.org/10.1002/mds.22102.
63. Morgan JC, Sethi KD. Drug-induced tremor. Lancet Neurol 2005;4:866– 876, doi: http://dx.doi.org/10.1016/S1474-4422(05)70250-7.
64. Emsley R, Turner HJ, Schronen J, et al. A single-blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia. J Clin Psychiatry 2004;65:696–701, doi: http://dx.doi.org/10.4088/JCP. v65n0516.
65. Jankovic J, Clarence-Smith K. Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders. Expert Review of Neurotherapeutics 2011;11:1509–1523, doi: http://dx.doi.org/10.1586/ern.11.149.
66. Jimenez-Shahed J, Jankovic J. Tetrabenazine for treatment of chorea associated with Huntington’s disease. Expert Opinion on Orphan Drugs 2013;1:423– 436, doi: http://dx.doi.org/10.1517/21678707.2013.787358.
67. Kenney C, Jankovic J. Tetrabenazine in the treatment of hyperkinetic movement disorders. Expert Rev Neurother 2006;6:7–17, doi: http://dx.doi.org/10.1586/14737175.6.1.7.
68. Fahn S. A therapeutic approach to tardive dyskinesia. J Clin Psychiatry 1985;46:19–24.
69. Angus S, Sugars J, Boltezar R, Koskewich S, Schneider NM. A controlled trial of amantadine hydrochloride and neuroleptics in the treatment of tardive dyskinesia. J Clin Psychopharmacol 1997;17:88–91, doi: http://dx.doi. org/10.1097/00004714-199704000-00004.
70. Soares KV, McGrath JJ, Deeks JJ. Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev 2001;(2): CD000203.
71. Thaker GK, Nguyen JA, Strauss ME, Jacobson R, Kaup BA, Tamminga CA. Clonazepam treatment of tardive dyskinesia: a practical GABAmimetic strategy. Am J Psychiatry 1990;147:445–451.
72. Stewart RM, Rollins J, Beckham B, et al. Baclofen in tardive dyskinesia patients maintained on neuroleptics. Clin Neuropharmacol 1982;5:365–373, doi: http://dx.doi.org/10.1097/00002826-198212000-00004.
73. Alabed S, Latifeh Y, Mohammad HA, Rifai A. Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev 2011;(4):CD000203.
74. Bergman J, Dwolatzky T, Brettholz I, Lerner V. Beneficial effect of donepezil in the treatment of elderly patients with tardive movement disorders. J Clin Psychiatry 2005;66:107–110, doi: http://dx.doi.org/10.4088/JCP. v66n0115.
75. Van Harten PN, Hoek HW, Matroos GE, van Os J. Evidence that lithium protects against tardive dyskinesia: the Curaçao Extrapyramidal syndromes study VI. Eur Neuropsychopharmacol 2008;18:152–155, doi: http://dx.doi.org/10.1016/j.euroneuro.2007.07.004.
76. McGrath J, Soares-Weiser K. Vitamin E for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev 2001;(4):CD000209.
77. Zhang XY, Zhou DF, Cao LY, Xu CQ, Chen DC, Wu GY. The effect of vitamin E treatment on tardive dyskinesia and blood superoxide dismutase: a double-blind placebo-controlled trial. J Clin Psychopharmacol 2004;24:83–86, doi: http://dx.doi.org/10.1097/01.jcp.0000104912.75206.2b.
78. Iwata Y, Irie S, Uchida H, Suzuki T, Watanabe K, Iwashita S, Mimura M. Effects of zonisamide on tardive dyskinesia: a preliminary open-label trial. J Neurol Sci 2012;315:137–140, doi: http://dx.doi.org/10.1016/j.jns.2011.12. 010.
79. Lerner V, Miodownik C, Kaptsan A, et al. Vitamin B6 in the treatment of tardive dyskinesia: a double-blind, placebo-controlled, crossover study. Am J Psychiatry 2001;158:1511–1514.
80. Shamir E, Barak Y, Shalman I, et al. Melatonin treatment for tardive dyskinesia: a double-blind, placebo-controlled, crossover study. Arch Gen Psychiatry 2001;58:1049–1052, doi: http://dx.doi.org/10.1001/archpsyc.58.11. 1049.
81. Waln O, Jankovic J. Zolpidem improves tardive dyskinesia and akathisia. Mov Disord 2013 doi:10.1002/mds.25480. [Epub ahead of print].
82. Jankovic J. Botulinum toxin. In: Kompoliti K, Verhagen Metman L, editors. Encyclopedia of movement disorders, 1st ed. Oxford: Academic Press; 2010. p 144–150.
83. Ramirez-Castaneda J, Jankovic J. Long-term efficacy, safety, and side effect profile of botulinum toxin injections in dystonia. Toxins 2013;5:249–266, doi: http://dx.doi.org/10.3390/toxins5020249.
84. Spindler MA, Galifianakis NB, Wilkinson JR, Duda JE. Globus pallidus interna deep brain stimulation for tardive dyskinesia: case report and review of the literature. Parkinsonism Relat Disord 2013;19:141–147, doi: http://dx.doi.org/10.1016/j.parkreldis.2012.09.016.
85. Wysokiński A. Intensive electroconvulsive therapy in drug resistant neuroleptic malignant syndrome – case report. Psychiatr Danub 2012;24:219– 222.
86. Aia PG, Revuelta GJ, Cloud LJ, Factor SA. Tardive dyskinesia. Curr Treat Options Neurol 2011;13:231–241, doi: http://dx.doi.org/10.1007/s11940-011-0117-x.
87. Fernandez HH, Friedman JH. Classification and treatment of tardive syndromes. Neurologist 2003;9:16–27, doi: http://dx.doi.org/10.1097/01.nrl. 0000038585.58012.97.